argenx SE (ARGX)
819.95
-26.32
(-3.11%)
USD |
NASDAQ |
Oct 16, 13:45
argenx SG&A Expense (TTM) : 1.537B for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.537B |
| December 31, 2025 | 1.370B |
| June 30, 2025 | 1.169B |
| December 31, 2024 | 1.053B |
| June 30, 2024 | 892.27M |
| December 31, 2023 | 713.00M |
| June 30, 2023 | 555.55M |
| December 31, 2022 | 471.68M |
| June 30, 2022 | 405.36M |
| December 31, 2021 | 306.92M |
| June 30, 2021 | 240.19M |
| December 31, 2020 | 178.74M |
| Date | Value |
|---|---|
| June 30, 2020 | 109.07M |
| December 31, 2019 | 72.19M |
| June 30, 2019 | 49.40M |
| December 31, 2018 | 32.31M |
| June 30, 2018 | 20.86M |
| December 31, 2017 | 10.51M |
| June 30, 2017 | 6.794M |
| December 31, 2016 | 4.903M |
| June 30, 2016 | 3.158M |
| December 31, 2015 | 2.798M |
| June 30, 2015 | 1.319M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Autolus Therapeutics Plc | 152.92M |
| Cellectis SA | 21.32M |
| Akari Therapeutics Plc | 8.796M |
| Forte Biosciences, Inc. | 10.25M |
| Halozyme Therapeutics, Inc. | 238.00M |